Showing posts with label Hormone. Show all posts
Showing posts with label Hormone. Show all posts

Sunday, November 29, 2009

Dark chocolate may lower stress hormone levels.

Moral of the story: Every wonder why dark chocolate makes you feel better? It changes your stress hormone metabolism. Cool.

Source: AMA Morning Rounds 11/13/09

Dark chocolate may lower stress hormone levels.

HealthDay (11/12, Dotinga) reported that "a dose of dark chocolate could cheer you right up by lowering your stress hormone levels," according to a study published online in the Journal of Proteome Research. After following 30 "volunteers who said they were highly stressed," researchers found that "a daily consumption of 40 grams [1.4 ounces] during a period of two weeks is sufficient to modify the metabolism of healthy human volunteers" by helping "correct other imbalances in the body that are related to stress." Reuters (11/13, Goldsmith) and also covers the story.

Thursday, February 5, 2009

Breast cancer risk rapidly drops after stopping hormone therapy

Moral of the story: hormone replacement therapy is a better predictor of breast cancer incidence than mammography frequency. If you are on homone replacement therapy, get those mammo's! Both the Reuters article and NEJM journal abstract are included below.

Breast cancer risk rapidly drops after stopping hormone therapy
By Reuters Health
February 5, 2009


NEW YORK (Reuters Health), Feb 5 - The elevated risk of breast cancer seen with combined hormone therapy quickly declines after this treatment is stopped, according to a report in the New England Journal of Medicine for February 5.

The results of the Women's Health Initiative (WHI) trial released in 2002 linked use of estrogen plus progestin with increased breast cancer risk in postmenopausal women. Subsequently, use of this therapy in the U.S. decreased substantially accompanied by a drop in breast cancer rates. Whether the two trends were causally related, however, was unclear.

In fact, it was suspected that changes in the frequency of mammographic screening may have accounted for the apparent drop in breast cancer incidence.

To investigate, Dr. Marcia Stefanick, from Stanford University School of Medicine, California, and colleagues analyzed follow-up data from the WHI trial. Included in the postintervention phase of the trial were 7,854 women who had received conjugated equine estrogens (0.625 mg) plus medroxyprogesterone (2.5 mg) daily and 7,533 given placebo.

In the two years prior to the intervention phase of the study, fewer breast cancer diagnoses were seen in the combined hormone therapy group than in the placebo group. During the 5.6 years of intervention, however, the risk of breast cancer was 26% higher in the hormone therapy group.

After stopping hormone therapy, the risk of breast cancer fell rapidly. The annualized incidence decreased 43% within one year, and by two years it was essentially the same as in the placebo group.

Moreover, during this period, "differences in the frequency of mammography between the two groups were unchanged."

Overall, "This is very strong evidence that estrogen plus progestin causes breast cancer," Stefanick said in a statement. "You start women on hormones and within five years, their risk for breast cancer is clearly elevated. You stop the hormones and within one year, their risk is essentially back to normal. It's reasonably convincing cause-and-effect data."

Last Updated: 2009-02-04 17:00:12 -0400 (Reuters Health)

Related Reading

Current HRT use is associated with low-grade breast cancer tumors, October 22, 2008


N Engl J Med 2009;360:573-587

NEJM -- Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women

NEJM -- Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women

Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Rowan T. Chlebowski, M.D., Ph.D., Lewis H. Kuller, M.D., Dr.P.H., Ross L. Prentice, Ph.D., Marcia L. Stefanick, Ph.D., JoAnn E. Manson, M.D., Dr.P.H., Margery Gass, M.D., Aaron K. Aragaki, M.S., Judith K. Ockene, Ph.D., Dorothy S. Lane, M.D., Gloria E. Sarto, M.D., Aleksandar Rajkovic, M.D., Ph.D., Robert Schenken, M.D., Susan L. Hendrix, D.O., Peter M. Ravdin, M.D., Ph.D., Thomas E. Rohan, M.B., B.S., Ph.D., Shagufta Yasmeen, M.D., Garnet Anderson, Ph.D., for the WHI Investigators


ABSTRACT

Background Following the release of the 2002 report of the Women's Health Initiative (WHI) trial of estrogen plus progestin, the use of menopausal hormone therapy in the United States decreased substantially. Subsequently, the incidence of breast cancer also dropped, suggesting a cause-and-effect relation between hormone treatment and breast cancer. However, the cause of this decrease remains controversial.

Methods We analyzed the results of the WHI randomized clinical trial — in which one study group received 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate daily and another group received placebo — and examined temporal trends in breast-cancer diagnoses in the WHI observational-study cohort. Risk factors for breast cancer, frequency of mammography, and time-specific incidence of breast cancer were assessed in relation to combined hormone use.

Results In the clinical trial, there were fewer breast-cancer diagnoses in the group receiving estrogen plus progestin than in the placebo group in the initial 2 years of the study, but the number of diagnoses increased over the course of the 5.6-year intervention period. The elevated risk decreased rapidly after both groups stopped taking the study pills, despite a similar frequency of mammography. In the observational study, the incidence of breast cancer was initially about two times as high in the group receiving menopausal hormones as in the placebo group, but this difference in incidence decreased rapidly in about 2 years, coinciding with year-to-year reductions in combined hormone use. During this period, differences in the frequency of mammography between the two groups were unchanged.

Conclusions The increased risk of breast cancer associated with the use of estrogen plus progestin declined markedly soon after discontinuation of combined hormone therapy and was unrelated to changes in frequency of mammography.